SAE Shop Apotheke Europe NV

EQS-News: Redcare Pharmacy's Annual General Meeting 2024 approved all agenda items. Dirk Brüse and Lode Fastré new members of the Managing Board.

EQS-News: Redcare Pharmacy N.V. / Key word(s): AGM/EGM/Personnel
Redcare Pharmacy's Annual General Meeting 2024 approved all agenda items. Dirk Brüse and Lode Fastré new members of the Managing Board.

18.04.2024 / 09:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Redcare Pharmacy's Annual General Meeting 2024 approved all agenda items. Dirk Brüse and Lode Fastré new members of the Managing Board.


Sevenum, the Netherlands, 18 April, 2024. At Redcare Pharmacy’s Annual General Meeting held yesterday, shareholders voted with an absolute majority for all agenda items, among others the appointment of Dirk Brüse as the new Chief Commercial Officer and Lode Fastré as the company’s new Chief Information Officer.

In addition, former Managing Board members and co-founders Stephan Weber (CCO) and Marc Fischer (CIO) were discharged from liability for the performance of their duties as members of the Managing Board.

As long-standing members of Redcare Pharmacy´s Senior Management Dirk Brüse and Lode Fastré have been mentored by Stephan Weber and Marc Fischer for many years. This transition comes at an ideal time, emphasising Redcare Pharmacy´s commitment to continuity, stability and sustainable growth. Stephan Weber and Marc Fischer will continue to support the company in an advisory capacity until 1 October 2026.

Olaf Heinrich, CEO of Redcare Pharmacy, expresses satisfaction with the investors’ approval stating: "We are very delighted that our shareholders approved the appointment of Dirk Brüse and Lode Fastré. With both, we have two strong leaders from our own ranks who embody the vision and culture of Redcare, along with the expertise to further advance our growth trajectory.”  

Other items on the agenda for this year's Annual General Meeting were the re-appointment of Björn Söder as a member of the Supervisory Board for an additional and fourth term of two years and the re-appointment of Jasper Eenhorst as a member of the Managing Board and CFO of the Company for a further term of four years.

Redcare Pharmacy’s business strategy has again proven successful in the first quarter of this year. The company will release official figures for Q1 on 25 April 2024.

Further information on the resolutions, including detailed voting results, can be found on our corporate website.

 

Investor Relations Contact:
Monica Ambrosi (Associate Director, Investor Relations)

 

Press Contact:
Sven Schirmer (Director, Corporate Communications)
 

 

About Redcare Pharmacy.

Originally founded in 2001, Redcare Pharmacy N.V. (formerly known as Shop Apotheke Europe N.V.) today is the leading e-pharmacy in Europe, currently active in seven countries: Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland.

Headquartered in Sevenum, close to the Dutch city of Venlo and in the heart of Europe, the company has locations in Cologne, Berlin, Munich, Tongeren, Warsaw, Milan, Lille and Eindhoven.

As the one-stop pharmacy of the future, Redcare Pharmacy offers over 11 million active customers a wide range of more than 150,000 products at attractive and fair prices. Besides OTC, nutritional supplements, beauty and personal care products as well as an extensive assortment of health-related products in all markets, the company also provides prescription drugs for customers in Germany, Switzerland and the Netherlands.

Pharmaceutical safety is of top priority. Being a pharmacy at its core, Redcare stands for comprehensive pharmaceutical consultation service. Since care is at the heart of everything Redcare does, the company provides services for all stages of life and health. This ranges from its marketplaces to unique delivery options and medication management.

Redcare Pharmacy N.V. has been listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard) since 2016. As of 19 June 2023, the company is a member of the MDAX selection index.

 



18.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


Language: English
Company: Redcare Pharmacy N.V.
Erik de Rodeweg 11-13
5975 WD Sevenum
Netherlands
Phone: 0800 - 200 800 300
Fax: 0800 - 90 70 90 20
E-mail:
Internet: -pharmacy.com
ISIN: NL0012044747, DE000A19Y072
WKN: A2AR94, A19Y072
Indices: MDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1882967

 
End of News EQS News Service

1882967  18.04.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1882967&application_name=news&site_id=research_pool
EN
18/04/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Shop Apotheke Europe NV

Charlotte Vaisse ... (+4)
  • Charlotte Vaisse
  • Jean-Baptiste Rouphael
  • Luis de Toledo Heras
  • Thomas Zlowodzki

ODDO BHF Small & MIDCAP MORNING NEWS - 04/25/2024

Having flirted with the 495-point mark on Friday, which could have triggered an extension of the correction, the market has rebounded well since then. Our technical analysis highlights a configuration in which we are only at the start of a powerful rally. Target of 622 points for Stoxx 600 index (+11%) by the end of the year confirmed. Prefer banks to insurance companies in the short term. - ...

Charlotte Vaisse ... (+4)
  • Charlotte Vaisse
  • Jean-Baptiste Rouphael
  • Luis de Toledo Heras
  • Thomas Zlowodzki

ODDO BHF Small & MIDCAP MORNING NEWS - 25/04/2024

Après avoir frôlé vendredi la barre des 495 points qui aurait pu déclencher la poursuite de la correction, le marché a ensuite bien rebondi. Notre analyse technique met en lumière une configuration où nous ne serions qu’au début d’un rallye puissant. Objectif 622 points (+11%) d’ici à la fin de l’année confirmé sur le Stoxx 600. Préférer les banques aux assurances à court terme. - ...

Andreas Riemann
  • Andreas Riemann

Redcare Pharmacy : Q1 profits below, FY 2024 targets confirmed

>Adjusted EBITDA below consensus - Early April, Redcare already pre-released Q1 2024 sales of € 560m (+51% y-o-y and +19% excluding M&A) which was a notch below expectations. Today, Redcare published Q1 profits below expectations. In Q1, adjusted EBITDA increased 33% y-o-y to € 11.7m (consensus: € 17m, ODDO BHFe: € 16.5m). This was € 5m or 30% below consensus. Compared to FY 2024 adjusted EBITDA this is an 8% miss. No details at this point but we think this may have t...

 PRESS RELEASE

EQS-News: Redcare setzt starkes zweistelliges Wachstum in Q1 bei posit...

EQS-News: Redcare Pharmacy N.V. / Schlagwort(e): Zwischenbericht/Quartals-/Zwischenmitteilung Redcare setzt starkes zweistelliges Wachstum in Q1 bei positiver Marge von 2,1% fort. Durchbruch bei Online-E-Rx in Deutschland nach vielen Jahren ebenfalls in Q1. 25.04.2024 / 06:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Redcare setzt starkes zweistelliges Wachstum in Q1 bei positiver Marge von 2,1% fort. Durchbruch bei Online-E-Rx in Deutschland nach vielen Jahren ebenfalls in Q1. Konzernumsatz von EUR 560 Mio. in Q1, ein Plus vo...

 PRESS RELEASE

EQS-News: Redcare’s fast double-digit growth continues in Q1, and at a...

EQS-News: Redcare Pharmacy N.V. / Key word(s): Interim Report/Quarterly / Interim Statement Redcare’s fast double-digit growth continues in Q1, and at a 2.1% positive margin. Also in Q1, after many years, breakthrough in online e-Rx in Germany. 25.04.2024 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Redcare’s fast double-digit growth continues in Q1, and at a 2.1% positive margin. Also in Q1, after many years, breakthrough in online e-Rx in Germany. Group sales of EUR 560M in Q1, up 51% from prior year. Non-Rx sales growth 20%...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch